Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. Co. is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. We show 2 historical shares outstanding datapoints in our coverage of TVRD's shares outstanding history.
Understanding the changing numbers of TVRD shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like TVRD versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching TVRD by allowing them to research TVRD shares outstanding history
as well as any other stock in our coverage universe. |
Free TVRD Email Alerts:
Video: Shares Outstanding Importance
